Jennifer Thery
Psychiatric/Mental Health · Maryville, ILNPI 1730509159
Payments from drug & device makers
Across 761 payments — averaging $108.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$52K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21K
- AbbVie$2K
- Johnson & Johnson$2K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$966
- plus $4K from 28 others
What the payments were for
- Consulting fees$7,6659%
- Speaking & faculty fees$57,53070%
- Travel & lodging$3,8135%
- Food & beverage$13,47416%
- Education$2620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 173 | $51,767 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $21,083 |
| AbbVie | 151 | $1,989 |
| Johnson & Johnson | 77 | $1,709 |
| Alkermes, Inc. | 68 | $1,072 |
| Otsuka America Pharmaceutical, Inc. | 64 | $966 |
| Neurocrine Biosciences, Inc. | 31 | $919 |
| Supernus Pharmaceuticals, Inc. | 19 | $703 |
| Axsome Therapeutics, Inc. | 21 | $569 |
| Livanova USA, Inc. | 6 | $249 |
| Lundbeck LLC | 10 | $229 |
| Ironshore Pharmaceuticals Inc. | 6 | $195 |
| E.r. Squibb & Sons, L.L.C. | 4 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $153 |
| Vanda Pharmaceuticals Inc. | 5 | $131 |
| Harmony Biosciences LLC | 1 | $125 |
| Collegium Pharmaceutical, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 2 | $109 |
| Almatica Pharma LLC | 4 | $81 |
| Tris Pharma Inc | 3 | $60 |
| Biogen | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 3 | $33 |
| Lilly USA, LLC | 1 | $33 |
| Orexo US, Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
| Gilead | 1 | $15 |
| Neuronetics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$20,865
- CAPLYTA$19,612
- UZEDY$15,222
- AUSTEDO$13,371
- LYBALVI$1,229
- INVEGA SUSTENNA$342
- QELBREE$317
- INGREZZA$246
- VRAYLAR$226
- VNS Therapy Symmetry Model 8103 Generator$133
- INVEGA TRINZA$126
- COBENFY$126
- Wakix$125
- JORNAY PM$125
- Auvelity$125
- REXULTI$100
How this compares
$82,743 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 106 | $693,594 |
| IngrezzaValbenazine Tosylate | 62 | $510,676 |
| AustedoDeutetrabenazine | 74 | $483,542 |
| Invega TrinzaPaliperidone Palmitate | 23 | $211,835 |
| CaplytaLumateperone Tosylate | 64 | $136,275 |
| VraylarCariprazine Hcl | 81 | $120,822 |
| Invega SustennaPaliperidone Palmitate | 32 | $95,743 |
| Abilify MaintenaAripiprazole | 28 | $83,735 |
| RexultiBrexpiprazole | 29 | $44,321 |
| UzedyRisperidone | 11 | $30,268 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,115 |
| SpravatoEsketamine Hcl | 11 | $13,926 |
| Aripiprazole | 179 | $10,906 |
| Paliperidone ErPaliperidone | 24 | $10,810 |
| TrintellixVortioxetine Hydrobromide | 17 | $10,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $51,767 | $1,207,404191 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $919 | $510,67662 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Spravato | $1,709 | $321,50466 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $21,083 | $136,27564 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $966 | $128,05757 claims |
| AbbVieVraylar | $1,989 | $120,82281 claims |
| Alkermes, Inc.Lybalvi | $1,072 | $19,11512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $153 | $10,20617 claims |
| Lilly USA, LLCOlanzapine | $33 | $3,757116 claims |
| Almatica Pharma LLCSertraline Hcl | $81 | $3,150424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Maryville
- Jaime MendozaMaryville$111K
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$162K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
- Julie CarbrayChicago$36K
- Doris van ByssumWheaton$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.